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SUMMARY
Background
Antibodies against tumour necrosis factor-alpha (anti-TNF) are effective therapies in
the treatment of ulcerative colitis (UC), but their comparative efﬁcacy is unknown.
Aim
To perform a network meta-analysis comparing the efﬁcacy of anti-TNF agents in UC.
Methods
After screening 506 studies, reviewers extracted information on seven studies. Tradi-
tional meta-analysis (TMA) was used to compare each anti-TNF agent to placebo.
Bayesian network meta-analysis (NMA) was performed to compare the effects of anti-
TNF agents to placebo. In addition, sample sizes for comparative efﬁcacy trials were
calculated.
Results
Compared to placebo, TMA revealed that anti-TNF agents result in a higher likelihood
of induction of remission and response (RR: 2.45, 95% CI: 1.72–3.47 and RR: 1.65, 95%
CI: 1.37–1.99 respectively) as well as maintenance of remission and response (RR: 2.00,
95% CI: 1.52–2.62 and RR: 1.76, 95% CI: 1.46–2.14 respectively). Individually, inﬂix-
imab, adalimumab and goliumumab resulted in a higher likelihood of induction and
maintenance for both remission and response. NMA found nonsigniﬁcant trends in
comparisons of the individual agents. The required sample sizes for direct head-to-head
trials between inﬂiximab and adalimumab for induction and maintenance are 174 and
204 subjects respectively.
Conclusions
This study demonstrates that, compared to placebo, inﬂiximab, adalimumab and goli-
mumab are all effective for the induction and maintenance of remission in ulcerative
colitis. However, network meta-analysis demonstrates that no single agent is clinically
superior to the others and therefore, other factors such as cost, safety, route of adminis-
tration and patient preference should dictate our choice of anti-TNF agents. A rando-
mised comparative efﬁcacy trial between inﬂiximab and adalimumab in UC is of
practical size and should be performed.
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INTRODUCTION
Ulcerative colitis (UC) is a chronic inﬂammatory disease
primarily affecting the colonic mucosa. UC is character-
ised by a relapsing and remitting course; treatments are
aimed at inducing and maintaining disease remission.
UC disease activity can result in reduced quality of life,
social and occupational disability, and increased health
care utilisation.1, 2 Direct costs of this condition are esti-
mated at US $3.4–8.6 billion and could be as high as US
$8.1–14.9 billion when accounting for the total economic
impact of UC.3 Medication use contributes to 25% of the
direct costs of UC. However, considering that hospitali-
sation represents nearly 50% of direct costs and ﬂares of
disease activity nearly double the mean economic impact
on the individual, improved disease control is likely to
reduce the net economic burden of UC.4
Antibodies against tumour necrosis factor-alpha
(anti-TNF) are effective therapies in the armamentarium
used to treat UC. Inﬂiximab is a chimeric monoclonal
antibody against soluble and membrane-bound TNF
with a murine Fc region. Adalimumab is fully human-
ised, but has similar action against TNF. A third
anti-TNF, golimumab was recently approved in 2013 for
moderate-to-severe UC. When assessed in individual
randomised controlled trials (RCT), these anti-TNF
therapies are approximately twice or more effective than
placebo for inducing and maintaining clinical response
and remission in UC.5–10
The comparative efﬁcacy of individual anti-TNF
therapies in UC has not been well studied. In Crohn’s
disease, the SWITCH randomised clinical trial suggested
that at approved standard dosing, adalimumab may be
less effective at inducing and maintaining remission than
inﬂiximab, although the data are inconclusive.11
Head-to-head clinical trials among individual anti-TNF
therapies have not been performed. Network meta-analy-
sis (NMA) uses the results of direct comparisons to a
common comparator (anti-TNF vs. placebo) to simulate
comparisons between individual anti-TNF agents, yield-
ing an estimate of comparative efﬁcacy. In the absence
of head-to-head RCTs, we employed both traditional and
network meta-analyses of inﬂiximab, adalimumab and
golimumab clinical trials to assess comparative efﬁcacy
between anti-TNF therapies for UC.
METHODS
Data sources and search
The study was conducted in accordance with the
PRISMA statement.12 The PubMed and Embase
databases were used primarily to identify potentially rel-
evant published, placebo-controlled randomised trials of
anti-TNF agents for ulcerative colitis. A search of
human studies in these databases from inception
through 31 August 2013 was performed using con-
trolled vocabulary descriptors (Medical Subject Headings
and Emtree) and speciﬁc keywords to represent the
concepts of the inﬂammatory bowel diseases and thera-
peutic use of anti-TNF blocking agents. The studies of
interest were placebo-controlled randomised, controlled
studies; retrospective and observational studies were not
included in any of the analyses.
The search was augmented by manual searches of ref-
erence lists from potentially relevant papers to identify
any additional studies that may have been missed using
the computer-assisted strategy. In addition, all available
guidelines, systematic reviews and meta-analyses pertain-
ing to the therapeutic use of anti-TNF blocking agents in
the inﬂammatory bowel diseases were reviewed for any
additional potentially relevant studies. The search was
not limited by language, though a large majority of the
manuscripts were originally published in English.
Study selection
Two investigators (TL, RS) independently reviewed the
titles of all identiﬁed citations to generate a list of
potentially relevant articles for further review. The
abstracts of these articles were reviewed to identify
studies suitable for inclusion in our ﬁnal analyses. For a
manuscript to be eligible for our study, it had to satisfy
the following eligibility criteria: (i) studies had to
examine the effect of a single anti-TNF agent on induc-
tion and/or maintenance of response or remission in
UC; (ii) the treatment of interest was an anti-TNF agent;
(iii) studies used the standard dosing regimen for the
examined anti-TNF agent; (iv) studies could not
duplicate data already published previously; (v) studies
were published as full manuscripts; (vi) response or
remission was deﬁned by a standardised scoring criteria
(typically Mayo score for UC); (vii) studies were
randomised, placebo-controlled trials with treatment and
control arms. Paediatric studies were excluded.
Data extraction
Two authors (TL and RS) independently extracted data
from the included studies via manual review. Discrep-
ancy between data extracted was resolved via consensus.
The following data points were extracted for each study:
ﬁrst author; year of publication; number of centres
involved (if multi-centre); drug studied, dosage and dose
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interval; blinding and randomisation; clinical endpoints
(induction or maintenance of either clinical response or
remission); the presence or absence of concomitant glu-
cocorticoid or immunosuppressive exposure; prior
anti-TNF agent exposure status; length of follow-up; the
presence of a drug washout period; the numbers of
patients in the treatment and control arms; the number
of patients in each arm who achieved induction of
response, induction of remission, maintenance of
response or maintenance of remission; the study’s mea-
surement of the primary outcome. Of note, for each
study, we used the number of patients randomised for
the intention-to-treat sample size.
Clinical endpoints
We extracted data to evaluate four clinical endpoints: (i)
Induction of Remission – deﬁned by the Mayo Score13
or Ulcerative Colitis Symptom Score13 within 8 weeks of
the initiation of the treatment; (ii) Induction of Response
– deﬁned as a decrease by at least 3 points and/or 30 per
cent from baseline in the total Mayo score, with an
accompanying decrease in the subscore for rectal
bleeding of at least 1 point or an absolute subscore for
rectal bleeding of 0 or 1; (iii) Maintenance of Remission
– induction of remission (as above) maintained for
minimum of 52 weeks; (iv) Maintenance of Response –
induction of response (as above) maintained for mini-
mum of 52 weeks.
Quality assessment
Two investigators (AD, DS) critically appraised and
quality rated all eligible studies. The randomised
controlled trials were assessed by criteria set forth by
the Evidence-Based Gastroenterology Steering Group
(EBGSG).14 These criteria were: (i) concealed random
allocation; (ii) blinding of patients and caregivers; (iii)
equal use of co-interventions for the treatment and
placebo groups; (iv) complete follow-up of study
patients; and (v) use of an intention-to-treat analysis.
Discrepancies in quality assessment were also resolved
by consensus.
Data synthesis and analysis
The outcomes analysed included induction and
maintenance of clinical response or remission in UC.
Traditional meta-analysis was used to calculate indirect
comparisons between anti-TNF drugs. Bayesian network
meta-analysis (NMA) was used to perform both direct
and indirect comparisons between different anti-TNF
drugs, using placebo as the common comparator.
Traditional meta-analysis was used for the direct
pairwise comparisons of each anti-TNF vs. placebo and
was performed using random-effects meta-analysis
techniques in Stata 13.0 (StataCorp, College Station, TX,
USA). The differences between random effects and ﬁxed
effects were also evaluated when only a single study for a
particular drug was evaluated. The Cochran Q test (v2)
and I2 inconsistency statistic (the percentage of total
variation across studies that are due to heterogeneity
rather than chance) were used to assess for statistical
heterogeneity between trials.15 When heterogeneity was
present, meta-inﬂuence analysis and Galbraith plot
assessment were performed to identify responsible outlier
studies. Pooled relative risks (RRs) and their 95%
conﬁdence intervals (95% CIs) were estimated for the
various anti-TNFs.
To compare the efﬁcacy of the anti-TNF agents, a
Bayesian network meta-analysis (NMA) was performed
with the GeMTC GUI statistical package.16 This form of
meta-analysis allows for the analysis of both direct and
indirect comparisons and generates estimates of effect
(with 95% credible intervals) for all possible pairwise
comparisons despite not being evaluated directly in a
head-to-head fashion in the included clinical trials. The
technique of NMA, in this situation, allows for the for-
mation of indirect comparisons between anti-TNF agents
using placebo as a common comparator. In addition, the
analysis allows for the ranking of different interventions
to evaluate the comparative efﬁcacy. For each individual
analysis, simulations were repeated 50 000 times to allow
convergence and an additional 50 000 simulations were
performed to produce the probability statements.
Convergence of iterations was evaluated using Gelman–
Rubin–Brooke statistic. For this analysis, Markov chain
Monte Carlo simulations were utilised to estimate
posterior distributions and a non-informative uniform
prior distribution of effect sizes and precision was used.
Sensitivity analyses
To assess the robustness of the results, separate tradi-
tional meta-analyses were repeated after: (i) eliminating
statistical heterogeneity by removing outlier studies, (ii)
excluding studies that used the UCSS instrument to
assess the outcome measure and (iii) excluding the
studies that continued maintenance therapy on those
that responded to the induction therapy to address any
variations in the study design.
Based on the results of this NMA, sample sizes for
between-drug comparative efﬁcacy studies were
calculated with the sampsi command in Stata 13.1,
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assuming 80% power and a two-sided alpha of 0.05. If
these direct head-to-head trials were used to inform
NMAs, Thorlund et al. have discussed additional meth-
ods to evaluate the power and precision (sample size) in
NMAs.17
RESULTS
Literature search
A ﬂow diagram depicting the search and selection pro-
cess is provided in Figure 1. Initial searches of the Med-
line and Embase databases yielded 486 citations. A
manual search of the PubMed.gov database for pertinent
systematic reviews, meta-analyses and guidelines identi-
ﬁed four summary documents, (a review of which
yielded 20 additional citations), totalling 506 citations.
Title review of these two groups of citations yielded 376
unique potentially relevant articles. Abstract and/or brief
manuscript review of these articles yielded 12 manu-
scripts appropriate for detailed evaluation. Seven of the
remaining manuscripts were included in the ﬁnal analy-
sis. Note that there were six individual manuscripts
included, but Rutgeerts et al. 2005 reported the results of
two separate randomised, controlled trials and therefore
each trial was included as a separate study. The remain-
ing ﬁve articles were excluded because they did not meet
eligibility criteria, as detailed in the ﬂow diagram. There
was 100% agreement between reviewers regarding ﬁnal
study selection.
Characteristics of included studies
Characteristics of the included studies are listed in
Table 1 and efﬁcacy data in Table 2. The seven studies
in six manuscripts meeting eligibility criteria included a
total of 1823 subjects for induction and 1070 subjects for
maintenance.5–10 No comparative efﬁcacy studies were
376 potentially relevant citations identified
12 studies¥ selected for manual review and 
eligibility
365 citations excluded after secondary screening
-96 were not relevant
-118 were redundant
-92 were guidelines or commentaries
-12 were test performance studies
-39 were relevant but were not RCTs
-8 were pediatric studies
486 citations identified using Medline, Embase, 
PubMed, and 20 citations from manual review 
of previously published systematic analyses
130 citations excluded for being review articles
5 manuscripts excluded
-3 were of insufficient quality to merit inclusion
-1 evaluated nonstandard endpoints
-1 evaluated a biologic agent that was not an anti-TNF
6 studies included in the network meta-analysis 
for induction of clinical remission in UC
5 studies included in the network meta-analysis 
for induction of clinical response in UC
6 studies evaluated anti-TNF agents for induction therapy
3 studies included in the network meta-analysis 
for maintenance of clinical remission in UC
3 studies included in the network meta-analysis 
for maintenance of clinical response in UC
3 studies evaluated anti-TNF agents for maintenance therapy
¥ - Rutgeerts et al. 2005 was a single manuscript that included the results for two separate 
randomized trials (ACT1 and ACT2) and the two studies are counted separately.
Figure 1 | Flow diagram of the search strategy and included studies in the analysis.
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identiﬁed; all included studies compared placebo to
various anti-TNF therapies. Three studies compared
inﬂiximab to placebo. Among these, three studies and
two studies evaluated remission and response, respec-
tively as an endpoint for induction (n = 529) and one
study evaluated remission and response as an endpoint
for maintenance (n = 242). Two studies compared ada-
limumab to placebo, of which both evaluated remission
and response as an endpoint for induction (n = 778)
and 1 evaluated remission and response as an endpoint
for maintenance (n = 518). Two studies compared goli-
mumab to placebo, of which 1 evaluated remission and
response as an endpoint for induction (n = 516) and the
other evaluated remission and response as an endpoint
for maintenance (n = 310).
Testing for heterogeneity between eligible studies
Pooled analysis of the effects of inﬂiximab, adalimumab
and golimumab on induction (remission and response)
and maintenance (remission and response) demonstrated
signiﬁcant statistical heterogeneity in only one situation,
i.e. the induction of remission among inﬂiximab studies
(I2 = 72.8%, P = 0.025). Meta-inﬂuence analysis and
visual inspection of Galbraith plots revealed that Rutge-
erts 2005 (ACT 2)9 was responsible for this heterogeneity
and was likely due to the high placebo rates.
Table 1 | Study characteristics of the included studies for the use of anti-TNFs for the treatment of ulcerative colitis
Study Drug Dosage Interval
Baseline meds
allowed
Previous anti-TNF:
Ctrl/Tx/Washout
Quality
score
Induction of clinical remission in ulcerative colitis
Reinisch et al.5
(ULTRA-1)
Adalimumab 160 mg, 80 mg,
40 mg, 40 mg SC
Every 2 Weeks CCS, 5-ASA, MCP,
AZA
Not allowed 5
Sandborn et al.6
(ULTRA-2)
Adalimumab 160 mg, 80 mg,
40 mg, 40 mg SC
Every 2 Weeks CCS, 5-ASA, MCP,
AZA
41.1%/39.1%/
2-month washout
5
Sandborn et al.7
(PURSUIT-SC)
Golimumab 200 mg,
then 100 mg SC
Week 0 and 2 CCS, 5-ASA, MCP,
AZA, MTX
Allowed; 12-month
washout
5
Probert et al.8 Inﬂiximab 5 mg/kg IV Week 0 and 2 CCS, MCP, 5-ASA,
AZA
Unknown but allowed;
3-month washout
4
Rutgeerts et al.9
(ACT 1)
Inﬂiximab 5 mg/kg IV Week 0, 2 and 6 CCS, 5-ASA, MCP,
AZA
Not allowed 5
Rutgeerts et al.9
(ACT 2)
Inﬂiximab 5 mg/kg IV Week 0, 2 and 6 CCS, 5-ASA, MCP,
AZA
Not allowed 5
Induction of clinical response in ulcerative colitis
Reinisch et al.5
(ULTRA-1)
Adalimumab 160 mg, 80 mg,
40 mg, 40 mg SC
Every 2 Weeks CCS, 5-ASA, MCP,
AZA
Not allowed 5
Sandborn et al.6
(ULTRA-2)
Adalimumab 160 mg, 80 mg,
40 mg, 40 mg SC
Every 2 Weeks CCS, 5-ASA, MCP,
AZA
41.1%/39.1%,
2-month washout
5
Sandborn et al.7
(PURSUIT-SC)
Golimumab 200 mg,
then 100 mg SC
Week 0 and 2 CCS, 5-ASA, MCP,
AZA, MTX
Allowed; 12-month
washout
5
Rutgeerts et al.9
(ACT 1)
Inﬂiximab 5 mg/kg IV Week 0, 2 and 6 CCS, 5-ASA, MCP,
AZA
Not allowed 5
Maintenance of clinical response and remission in ulcerative colitis
Sandborn et al.6
(ULTRA-2)
Adalimumab 40 mg SC Every 2 Weeks
after induction
CCS, 5-ASA, MCP,
AZA
41.1%/39.1%/
2-month washout
5
Sandborn et al.10
(PURSUIT-M)
Golimumab 100 mg SC Every 4 Weeks
after induction
CCS, 5-ASA, MCP,
AZA, MTX
Allowed; 12-month
washout
5
Rutgeerts et al.9
(ACT 1)
Inﬂiximab 5 mg/kg IV Every 8 Weeks
after induction
CCS, 5-ASA, MCP,
AZA
Not allowed 5
CCS, corticosteroids; 5-ASA, 5-aminosalicylates; MCP, mercaptopurine; AZA, azathioprine; MTX, methotrexate.
Washout in all cases refers to a period free of Anti-TNF agents if previous receipt of Anti-TNF agents was allowed.
Quality Score deﬁned by the Evidence-Based Gastroenterology Steering Group’s system (EBGSG). It is a 5-point system used to
assess the rigour of randomised controlled trials. The individual points are awarded for (i) concealed random allocation; (ii) blind-
ing of patients and caregivers; (iii) equal use of co-interventions for the treatment and placebo groups; (iv) complete follow-up of
study patients; and (v) use of an intention-to-treat analysis. A perfect score of 5 indicates a high quality study and lower scores
indicate lower quality studies.
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Meta-analysis results
Induction of remission and response. Compared to pla-
cebo, traditional meta-analysis revealed that anti-TNF
agents result in a 2.45-fold higher likelihood of induc-
tion of remission and 1.65-fold higher likelihood of
induction of response compared to placebo (RR: 2.45,
95% CI: 1.72–3.47 and RR: 1.65, 95% CI: 1.37–1.99
respectively). Individually, inﬂiximab resulted in a
2.76-fold higher likelihood of inducing remission and
2-fold higher likelihood of inducing response compared
to placebo (RR: 2.76, 95% CI: 1.29–5.90 and RR: 2.00,
95% CI: 1.64–2.44 respectively). Adalimumab resulted
in a 1.87-fold higher likelihood of inducing remission
and 1.36-fold higher likelihood of inducing response
compared to placebo (RR: 1.87, 95% CI: 1.27–2.75 and
RR: 1.36, 95% CI: 1.13–1.64 respectively). Golimumab
resulted in a 3-fold higher likelihood of inducing
remission and 1.75-fold higher likelihood of inducing
response compared to placebo (RR: 3.00, 95% CI: 1.75–
5.14 and RR: 1.75, 95% CI: 1.40–2.19 respectively).
(Figure 2a, b).
Network meta-analysis of agents for induction of
remission did not show signiﬁcant differences between
agents (RR: 2.08 for inﬂiximab vs. adalimumab, 95% CrI:
0.32–12.03; RR: 1.18 for inﬂiximab vs. golimumab, 95%
CrI: 0.13–10.63; and RR: 1.75 for adalimumab vs. goli-
mumab, 95% CrI: 0.17–16.86). While trends favoured
inﬂiximab over both adalimumab and golimumab, the
95% credible interval crossed 1 and was therefore not
statistically signiﬁcant. Inﬂiximab was ranked the most
effective drug in 55% of the simulations, while goli-
mumab was favoured in 36% and adalimumab in 9%.
Similarly, the network meta-analysis of agents for the
induction of response demonstrated no statistically sig-
niﬁcant differences between agents (RR: 2.15 for inﬂix-
imab vs. adalimumab, 95% CrI: 0.73–5.80; RR: 1.48 for
Table 2 | Efﬁcacy data of the included studies for the use of anti-TNFs for the treatment of ulcerative colitis
Study Drug Endpoint
Follow-up
(weeks)
Results
Control (%)
Anti-TNF
(%)
Induction of clinical remission in ulcerative colitis
Reinisch et al.5 (ULTRA-1) Adalimumab Clinical remission (Mayo score) 8 12/130 (9.2) 24/130 (18.5)
Sandborn et al.6 (ULTRA-2) Adalimumab Clinical remission (Mayo score) 8 23/260 (8.8) 41/258 (15.9)
Sandborn et al.7
(PURSUIT-SC)
Golimumab Clinical Remission (Mayo score) 6 16/258 (6.2) 48/258 (18.6)
Probert et al.8 Inﬂiximab Clinical remission (Mayo score) 6 6/20 (30.0) 9/23 (39.1)
Rutgeerts et al.9 (ACT 1) Inﬂiximab Clinical Remission (Mayo score) 8 18/121 (14.9) 47/121 (38.8)
Rutgeerts et al.9 (ACT 2) Inﬂiximab Clinical remission (Mayo score) 8 33/123 (26.8) 41/121 (33.9)
Induction of clinical response in ulcerative colitis
Reinisch et al.5 (ULTRA-1) Adalimumab Clinical response (Mayo score) 8 58/130 (44.6) 71/130 (54.6)
Sandborn et al.6 (ULTRA-2) Adalimumab Clinical response (Mayo score) 8 85/260 (32.7) 125/258 (48.4)
Sandborn et al.7
(PURSUIT-SC)
Golimumab Clinical response (Mayo score) 6 76/258 (29.5) 133/258 (51.6)
Rutgeerts et al.9 (ACT 1) Inﬂiximab Clinical response (Mayo score) 8 45/121 (37.2) 84/121 (69.4)
Maintenance of clinical remission in ulcerative colitis
Sandborn et al.6 (ULTRA-2) Adalimumab Clinical remission (Mayo score) 52 21/260 (8.1) 43/258 (16.7)
Sandborn et al.10
(PURSUIT-M)
Golimumab Clinical remission (Mayo score) 52 24/156 (15.4) 44/154 (28.6)
Rutgeerts et al.9 (ACT 1) Inﬂiximab Clinical remission (Mayo score) 54 20/121 (16.5) 42/121 (34.7)
Maintenance of clinical response in ulcerative colitis
Sandborn et al.6 (ULTRA-2) Adalimumab Clinical response (Mayo score) 52 45/260 (17.3) 75/258 (29.1)
Sandborn et al.10
(PURSUIT-M)
Golimumab Clinical response (Mayo score) 52 49/156 (31.4) 78/154 (50.6)
Rutgeerts et al.9 (ACT 1) Inﬂiximab Clinical response (Mayo score) 54 24/121 (19.8) 55/121 (45.5)
Remission by Mayo Score deﬁned as total mayo score ≤2 with no individual subscore >1.
Remission by Ulcerative Colitis Symptom Score deﬁned as UCSS ≤2.
Clinical Response by Mayo Score deﬁned as a decrease from baseline in the total Mayo score of at least 3 points and at least 30
per cent, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore for rectal
bleeding of 0 or 1.
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NOTE: Weights are from random effects analysis
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Sandborn (2012)
Rutgeerts (2005)
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Reinisch (2011)
Golimumab
ID
Subtotal  (X 2 = 0.07, df 1,I2 = 0.0%, P = 0.794)
Probert (2003)
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Adalimumab
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NOTE: Weights are from random effects analysis
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Overall (X 2 = 11.10, df 4,I2 = 64.0%, P = 0.025)
Infliximab
Study
Sandborn (2013)
Subtotal (X 2 = 1.32, df 1,I2 = 24.1%, P = 0.251)
Reinisch (2011)
Golimumab
Subtotal (X 2 = 0.66, df 1,I2 = 0.0%, P = 0.417)
ID
Rutgeerts (2005)
Adalimumab
Sandborn (2012)
Rutgeerts (2005)
Subtotal  (I2 = .%, P = .)
1.65 (1.37, 1.99)
1.75 (1.40, 2.19)
1.36 (1.13, 1.64)
1.22 (0.96, 1.57)
2.00 (1.64, 2.44)
RR (95% CI)
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%
100.00
100.00
44.71
100.00
Weight
57.90
55.29
42.10
100.00
.335 1 2.99
(b)
Figure 2 | Panel: Meta-analysis of anti-TNFs for the treatment of ulcerative colitis. (a) Meta-analysis of the induction
of remission endpoint. (b) Meta-analysis of the induction of response endpoint. (c) Meta-analysis of the maintenance
of remission endpoint. (d) Meta-analysis of the maintenance of response endpoint.
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NOTE: Weights are from random effects analysis
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Figure 2 | Continued.
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inﬂiximab vs. golimumab, 95% CrI: 0.38–4.69; and RR:
1.46 for golimumab vs. adalimumab, 95% CrI:
0.42–5.38). Again, trends favoured inﬂiximab over both
adalimumab and golimumab; however, the 95% credible
interval crossed 1 and was therefore not statistically
signiﬁcant. Inﬂiximab was ranked the most effective drug
in 80% of the simulations, while golimumab was
favoured in 17% and adalimumab in 3%.
Maintenance of remission and response
Compared to placebo, traditional meta-analysis revealed
that anti-TNF agents result in a 2.00-fold higher likeli-
hood of maintenance of remission and 1.76-fold higher
likelihood of maintenance of response compared to pla-
cebo (RR: 2.00, 95% CI: 1.52–2.62 and RR: 1.76, 95% CI:
1.46–2.14 respectively). Individually, inﬂiximab resulted
in a 2.10-fold higher likelihood of maintaining remission
and 2.29-fold higher likelihood of maintaining response
compared to placebo (RR: 2.10, 95% CI: 1.31–3.36 and
RR: 2.29, 95% CI: 1.52–3.45 respectively). Adalimumab
resulted in a 2.06-fold higher likelihood of maintaining
remission and 1.68-fold higher likelihood of maintaining
response compared to placebo (RR: 2.06, 95% CI: 1.26–
3.38 and RR: 1.68, 95% CI: 1.21–2.33 respectively).
Golimumab resulted in a 1.86-fold higher likelihood of
maintaining remission and 1.61-fold higher likelihood of
maintaining response compared to placebo (RR: 1.86,
95% CI: 1.19–2.90 and RR: 1.61, 95% CI: 1.22–2.13
respectively – Figure 2C, D).
Network meta-analysis of agents for maintenance of
remission did not show signiﬁcant difference between
agents (RR: 1.18 for inﬂiximab vs. adalimumab, 95% CrI:
0.19–8.02, RR: 1.22 for inﬂiximab vs. golimumab, 95%
CrI: 0.18–8.43, RR: 1.04 for adalimumab vs. golimumab,
95% CrI: 0.16–6.96). While trends favoured inﬂiximab
over both adalimumab and golimumab, the 95% credible
interval crossed 1 and was therefore not statistically sig-
niﬁcant. Inﬂiximab was ranked the most effective drug
in 45% of the simulations, while adalimumab was
favoured in 28% and golimumab in 26%.
Finally, the network meta-analysis of agents for the
maintenance of response demonstrated no statistically
signiﬁcant difference between agents (RR: 1.70 for inﬂix-
imab vs. adalimumab, 95% CrI: 0.17–16.59, RR: 1.47 for
inﬂiximab vs. golimumab, 95% CrI: 0.15–14.43, RR: 1.14
for adalimumab vs. golimumab, 95% CrI: 0.11–10.92).
While trends favoured Inﬂiximab over both adalimumab
and golimumab, the 95% credible interval crossed 1 and
was therefore not statistically signiﬁcant. Inﬂiximab was
ranked the most effective drug in 61% of the simulations,
while golimumab was favoured in 22% and adalimumab
in 17%.
Direct comparison sample size estimations
Using data generated by our NMA, the required sample
sizes for direct comparative efﬁcacy trials between
anti-TNF agents were calculated (Table 3). Comparison of
inﬂiximab to adalimumab with 90% power would require
174 and 204 subjects to determine whether superiority
exists between these agents for induction and maintenance
respectively. Direct comparison of inﬂiximab to goli-
mumab would require 214 and 1870 subjects to determine
superiority for induction and maintenance, respectively.
Publication bias
The funnel plot asymmetry test for publication bias was
negative for all outcomes using the Harbord test
(P = 0.44) for induction of remission; (P = 0.64) for
induction of response; (P = 0.59) for maintenance of
remission; (P = 0.27) for maintenance of response.
Sensitivity analyses
The sensitivity analyses did not substantively change the
results. Speciﬁcally, excluding outlier studies [n = 1,
Rutgeers 2005 (ACT 29)], studies that use the UCSS
instrument to assess the outcome measure (n = 1, Prob-
ert 20038), and studies that continued maintenance ther-
apy on those that responded to the induction therapy
(n = 1, Sandborn et al.10) in separate sensitivity tradi-
tional meta-analyses did not substantively affect compos-
ite treatment effects.
DISCUSSION
This study demonstrates that anti-TNF agents, as a class,
are more effective than placebo for both inducing and
maintaining clinical response and remission in UC.
However, the comparative efﬁcacy of competing agents
and the potential superiority of inﬂiximab for ulcerative
Table 3 | Total number of subjects required for
comparative effectiveness RCTs between anti-TNF
drugs for UC induction and maintenance
Total subject number (Induction/
Maintenance)
Inﬂiximab Golimumab Adalimumab
Inﬂiximab – 214/1870 174/204
Golimumab 214/1870 – 13 562/420
Adalimumab 174/204 13 562/420 –
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colitis remains a debated issue. Our study is the ﬁrst to
compare these agents through a network meta-analysis.
We found that there is no clear evidence of the superior-
ity of any agent over the others, although there was a
trend towards higher rates of remission and response
with inﬂiximab.
There are no head-to-head randomised comparisons of
anti-TNF agents; however, observational and nonrando-
mised studies support similar efﬁcacy among anti-TNF
therapies.18–20 Retrospective studies performed in Crohn’s
disease and rheumatoid arthritis also failed to demonstrate
any difference in efﬁcacy between adalimumab and
inﬂiximab. For example, studies from the Netherlands and
using US Medicare claims data found that CD patients
receiving inﬂiximab or adalimumab had similar rates of
steroid avoidance, surgery and hospitalisation.21, 22
Sample size estimated using data generated by our
NMA, demonstrated that while some comparative efﬁcacy
trials would require impractical sample sizes (adalimumab
vs. golimumab induction, 13 562), others are quite feasible
(inﬂiximab vs. adalimumab induction, 174). These sample
size estimates suggest that differential efﬁcacy between go-
limumab and adalimumab may be small, but that impor-
tant information could be gained from a direct
comparative efﬁcacy trial between inﬂiximab and ada-
limumab, and should be performed. The results of such a
trial could be used to help patients make more informed
decisions about the optimal choice of agents.
In the meantime, given the lack of head-to-head trials
and the lack of clear evidence of clinical superiority of
one TNF agent in our analysis, providers should base
their choice of TNF agent on other factors including
cost, safety, route of administration and patient prefer-
ences. There are a limited number of studies on compar-
ative cost effectiveness of anti-TNF agents. One study in
CD suggested that adalimumab could result in signiﬁcant
cost savings of US$7000 over a 1-year period compared
to inﬂiximab.23 Similar savings were observed in the
United Kingdom without signiﬁcant increases in
hospitalisation, surgery or diagnostic studies and
procedures, despite allowing for adalimumab dose escala-
tion where clinically indicated.24 Generally, safety is
believed to be comparable between the anti-TNF thera-
pies, and this has recently been comprehensively evalu-
ated in a multiple meta-analysis for various side effects
such as the risk of melanoma,25 opportunistic infec-
tions26 and lymphoma.27, 28 In addition, there is data to
suggest that inﬂiximab may have higher rates of intoler-
ance and allergy.29 Survey studies report that patient
choice of anti-TNF drug is most inﬂuenced by route of
administration, with a preference for subcutaneous thera-
pies over infusion-based therapies.30, 31 In the absence of
demonstrated variation in efﬁcacy, economics, safety and
patient preference may argue for considering subcutane-
ous therapies prior to infusion-based therapies when
selecting anti-TNF therapy for UC.
Several limitations of this study impact interpretation
of the reported results. In both NMAs and TMAs, statis-
tical and clinical heterogeneity should be evaluated and
this process includes assessing study quality and
evaluating bias.
In our meta-analysis, the literature search only identi-
ﬁed placebo-controlled RCTs, without any head-to-head
comparisons; nonetheless there were notable variations
in study design and conduct. For example, we included
the study from Probert et al., which used the UCSS tool
in place of the full Mayo score to measure disease
activity. However, sensitivity analysis did not reveal any
signiﬁcant change in the point estimate if this study was
not included. Similarly, the golimumab study was per-
formed with a different maintenance study methodology
compared to the inﬂiximab and adalimumab studies. In
the golimumab maintenance study, only patients who
responded to initial induction were re-randomised to
golimumab or placebo. Excluding the golimumab study
from the TMA did not signiﬁcantly change the results
but did limit the analysis to only 2 studies.
Heterogeneity in placebo remission rates between
ACT-1 and 2 (14.9–16.5% at week 8 and 54), and
ULTRA-1 and 2 (8.5–9.3%), suggest that variations in
study conduct or design were present, and these were eval-
uated in sensitivity analysis. Heterogeneity in placebo rates
remains a prevalent issue in inﬂammatory bowel disease
research with no clear consensus on a single mechanism
but include selection of patients, clinical characteristics,
timing of clinical evaluation and inter-observer variation
as suggested by Renna et al.32 Others have proposed alter-
native endpoints in the evaluation of inﬂammatory bowel
disease trials, but this has not been widely adopted.33
One additional concern for NMAs is that, while we
assume that studies can be combined, these assumptions
must hold true over the entire network, including
evaluation of the indirect comparisons between existing
studies. Unfortunately, in our study, the validity of this
assumption could not be evaluated, as head-to-head tri-
als between anti-TNFs do not exist. Financial and market
incentives will likely prevent head-to-head trials between
anti-TNF agents for the foreseeable future, which makes
this NMA the only comparative data we are likely to
have. More complex assumptions do exist for NMAs,
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but these are not statistically based and rely on expert
consensus.34, 35
Further, the Bayesian-driven approach used in this net-
work meta-analysis assumed non-informative priors for
treatment effects and assumed a homogenous variance
between studies, which is the most common approach in
NMA.36 These unbiased assumptions are considered the
most conservative approach, but may reduce the probabil-
ity of identifying signiﬁcant differences between treat-
ments. Thorlund et al. have suggested that using
informative priors to estimate variance may lead to more
precise analyses and thereby increase the probability that
statistically signiﬁcant differences may be found between
treatments.37 The decision of whether to use informative
or non-informative priors for network meta-analysis and
mixed treatment comparisons remains controversial.
However, a recent report by the Agency for Healthcare
Research and Quality (AHRQ) evaluated various studies
that used mixed treatment comparisons and concluded
that based on the current literature they do not believe
that there is enough data to support using informative
priors.38 Therefore, we used the more conservative
approach of non-informative priors in this study, which
may have limited our study’s ability to detect signiﬁcant
differences between the therapies. This is the primary bias
in our approach, in that by choosing a conservative
approach, we make it less likely to have a type I error
(false positive ﬁnding) and more likely to have a type II
error (false negative or absence of a difference).
Taking all this into account, NMAs provide estimates
of the relative treatment effects in addition to 95% credi-
ble intervals. This in turn can be used to calculate the
probability of how efﬁcacious the therapy is compared to
the other therapies as detailed above. In conclusion, inf-
liximab, adalimumab and golimumab are all effective
agents to induce and maintain clinical response in ulcer-
ative colitis. However, network meta-analysis demon-
strates that no single agent is clinically superior to the
others and therefore, other factors such as cost, safety,
route of administration and patient preferences should
dictate our choice of anti-TNF therapy as we await the
results of comparative efﬁcacy trials. A network
meta-analysis in the absence of head-to-head studies may
not be able to detect small differences between anti-TNF
therapies that do exist (type II error). We have excluded
large therapeutic differences with the NMA.
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